ACP Diabetes Monthly
Welcome to this month's issue of ACP Diabetes Monthly, an update for internists published by the American College of Physicians.
In the News for the month of August 2016
HbA1c variability linked to risk of adverse long-term outcomes in type 2 diabetes
The effect of HbA1c variability on outcomes, including mortality, myocardial infarction, and stroke, appeared to be independent of directional trends or baseline HbA1c level. More...
Incretin-based drugs not associated with higher risk of pancreatitis in large, population-based study
The findings of this study should provide some reassurance to patients treated with incretin-based drugs, according to the authors. More...
Very low systolic blood pressure associated with less CV risk in diabetes patients
Patients with type 2 diabetes and a systolic blood pressure of 110 to 119 mm Hg appeared to have a lower risk of cardiovascular disease than patients who had systolic blood pressures of 130 to 139 mm Hg, according to a registry study. More...
MKSAP quiz: Hypertension treatment with newly diagnosed diabetes
This month's quiz asks readers to evaluate a 51-year-old man who was recently diagnosed with hypertension and diabetes mellitus. More...
From ACP Journal Club
In insulin-treated type 1 diabetes, canagliflozin increased diabetic ketoacidosis
Taking canagliflozin, at a dose of either 100 mg or 300 mg per day, was associated with risk of diabetic ketoacidosis, according to a trial that randomized patients with type 1 diabetes to either of the doses or a placebo. More...
Incretin-based drugs were not linked to HF hospitalization compared with other oral antidiabetic drug combinations
Incretin-based drugs did not appear to be associated with greater heart failure hospitalization risk compared with commonly used combinations of oral antidiabetic drugs, a cohort study found. More...
From ACP Internist Weekly
GLP-1 analogues may be associated with bile duct, gallbladder disease
Current use of DPP-4 inhibitors was not associated with increased risk for bile duct and gallbladder disease versus current use of at least 2 oral antidiabetic drugs, but an increased risk was seen with use of GLP-1 analogues. More...
New daily injection approved for adults with type 2 diabetes
Lixisenatide (Adlyxin), a once-daily injection, was approved by the FDA on July 28 to improve glycemic control in adults with type 2 diabetes. More...
Spotlight on telehealth for diabetes management
Two recent studies analyzed telehealth interventions to improve glycemic control among patients with type 2 diabetes and high HbA1c levels. More...
Physician editor: David V. O'Dell, MD, FACP
Has Your Contact Information Changed?
To change your e-mail address or other contact information in our records, go here or call 800-523-1546, ext. 2600 (M-F, 9 a.m. - 5 p.m. ET).
About ACP Diabetes Monthly
ACP Diabetes Monthly is a monthly newsletter produced by the staff of ACP Internist. It is automatically sent to all College members who have an e-mail address on file with ACP.
To add your e-mail address to your member record and to begin receiving ACP Diabetes Monthly, please click here.
Copyright © by American College of Physicians.
A 54-year-old man is evaluated during follow-up consultation regarding laboratory studies completed for a life insurance policy. He reports no symptoms. A bone marrow biopsy shows trilineage dysplasia with 1% blasts. Results of cytogenetic testing show loss of the Y chromosome (-Y). What is the most appropriate management?
Not an ACP Member?
Join today and discover the benefits waiting for you.
ACP offers different categories of membership depending on your career stage and professional status. View options, pricing and benefits.
A New Way to Ace the Boards!
Ensure you're board-exam ready with ACP's Board Prep Ace - a multifaceted, self-study program that prepares you to pass the ABIM Certification Exam in internal medicine. Learn more.